In conclusion, our results indicate that treatment with PT in combination with Sal enhances autophagy-dependent cell death through the involvement of the p-eIF2α/ATF4/LC3 pathway and may represent a novel anticancer agent for HCC treatment. This evidence concerns the gene MAP1LC3A and hepatocellular carcinoma.